NASDAQ:EDIT - Editas Medicine Stock Price, Price Target & More

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine Inc (NASDAQ:EDIT) announced its earnings results on Thursday, May, 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.82) by $0.15. The business earned $3.90 million during the quarter, compared to analyst estimates of $4.04 million. Editas Medicine had a negative return on equity of 58.73% and a negative net margin of 707.98%. Editas Medicine's revenue for the quarter was up 473.5% compared to the same quarter last year. During the same period last year, the company earned ($0.85) EPS. View Editas Medicine's Earnings History.

Editas Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Editas Medicine.

9 equities research analysts have issued 1-year price objectives for Editas Medicine's stock. Their predictions range from $27.00 to $67.00. On average, they anticipate Editas Medicine's share price to reach $47.1667 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price. View Analyst Ratings for Editas Medicine.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Editas Medicine include BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Solid Biosciences (SLDB) and Sangamo Therapeutics (SGMO).

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

News headlines about EDIT stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Editas Medicine earned a media sentiment score of 0.06 on Accern's scale. They also gave headlines about the company an impact score of 45.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.25%), Cornerstone Wealth Management LLC (0.04%), Boston Advisors LLC (0.02%), Amalgamated Bank (0.01%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman, Kevin P Starr, Polaris Venture Management Co and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.

EDIT stock was purchased by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Cornerstone Wealth Management LLC, Boston Advisors LLC, Amalgamated Bank and Xact Kapitalforvaltning AB. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $36.25.

Editas Medicine has a market capitalization of $1.71 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]